What is Treace Medical Concepts, Inc.'s earnings per share (EPS)?

Treace Medical Concepts, Inc. (TMCI) reported diluted earnings per share of $-0.93 for fiscal year 2025. This represents a -3.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Treace Medical Concepts, Inc. Financials

TMCI

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Treace Medical Concepts, Inc. (TMCI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TMCI FY2025 2026-05-08

A near-80.0% gross-margin model is still constrained by a commercial cost structure that revenue growth has not yet absorbed.

By FY2025, operating cash burn improved to -$16.0M even as net loss widened to -$59.0M. That earnings-to-cash gap suggests losses were increasingly shaped by non-cash charges and working-capital release, so cash strain eased more than the income statement alone implies and the burn became less punitive in day-to-day operations.

With gross margin still near 80.0% and operating margin still around -25.0%, the core product economics appear much stronger than the company-level economics. That points to a scaling problem above the gross-profit line, where selling, administrative, and development spending still consume the contribution created by each additional sale instead of letting it fall through to profit.

Even after cash burn improved, capital spending of $13.5M kept free cash flow at -$29.5M, so the business is not yet self-funding. The balance sheet also looks more liquid on paper than in cash terms, because cash of $10.7M is modest beside long-term debt of $55.6M, which means liquidity depends more on converting receivables and inventory than on a large cash cushion.

Financial Health Signals

Financial Health Score 46/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Treace Medical Concepts, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Treace Medical Concepts, Inc. has an operating margin of -25.5%, meaning the company retains $-25 of operating profit per $100 of revenue. This results in a moderate score of 35/100, indicating healthy but not exceptional operating efficiency. This is up from -26.6% the prior year.

Growth

Treace Medical Concepts, Inc.'s revenue grew a modest 1.6% year-over-year to $212.7M. This slow but positive growth earns a score of 56/100.

Leverage

Treace Medical Concepts, Inc. has a moderate D/E ratio of 0.64. This balance of debt and equity financing earns a leverage score of 55/100.

Liquidity

With a current ratio of 4.31, Treace Medical Concepts, Inc. holds $4.31 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.

Cash Flow

While Treace Medical Concepts, Inc. generated -$16.0M in operating cash flow, capex of $13.5M consumed most of it, leaving -$29.5M in free cash flow. This results in a low score of 12/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Treace Medical Concepts, Inc.'s ROE of -67.6% shows moderate profitability relative to equity, earning a score of 30/100. This is down from -49.4% the prior year.

Altman Z-Score Distress

0.61

Treace Medical Concepts, Inc. scores 0.61, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($279.0M) relative to total liabilities ($103.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Treace Medical Concepts, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.27x

For every $1 of reported earnings, Treace Medical Concepts, Inc. generates $0.27 in operating cash flow (-$16.0M OCF vs -$59.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-10.2x

Treace Medical Concepts, Inc. earns $-10.2 in operating income for every $1 of interest expense (-$54.2M vs $5.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$212.7M

YoY+1.6%

5Y CAGR+30.0%

Treace Medical Concepts, Inc. generated $212.7M in revenue in fiscal year 2025. This represents an increase of 1.6% from the prior year.

EBITDA

-$43.5M

YoY+7.9%

Treace Medical Concepts, Inc.'s EBITDA was -$43.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.9% from the prior year.

Net Income

-$59.0M

YoY-5.8%

Treace Medical Concepts, Inc. reported -$59.0M in net income in fiscal year 2025. This represents a decrease of 5.8% from the prior year.

EPS (Diluted)

$-0.93

YoY-3.3%

Treace Medical Concepts, Inc. earned $-0.93 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 3.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$29.5M

YoY+39.5%

Treace Medical Concepts, Inc. generated -$29.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 39.5% from the prior year.

Cash & Debt

$10.7M

YoY-5.7%

5Y CAGR-9.9%

Treace Medical Concepts, Inc. held $10.7M in cash against $55.6M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

79.8%

YoY-0.6pp

5Y CAGR+1.6pp

Treace Medical Concepts, Inc.'s gross margin was 79.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.6 percentage points from the prior year.

Operating Margin

-25.5%

YoY+1.1pp

5Y CAGR-27.0pp

Treace Medical Concepts, Inc.'s operating margin was -25.5% in fiscal year 2025, reflecting core business profitability. This is up 1.1 percentage points from the prior year.

Net Margin

-27.7%

YoY-1.1pp

5Y CAGR-21.3pp

Treace Medical Concepts, Inc.'s net profit margin was -27.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.1 percentage points from the prior year.

Return on Equity

-67.6%

YoY-18.2pp

5Y CAGR+405.1pp

Treace Medical Concepts, Inc.'s ROE was -67.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 18.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$20.3M

YoY-1.5%

5Y CAGR+28.2%

Treace Medical Concepts, Inc. invested $20.3M in research and development in fiscal year 2025. This represents a decrease of 1.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$13.5M

YoY+16.6%

5Y CAGR+66.1%

Treace Medical Concepts, Inc. invested $13.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 16.6% from the prior year.

TMCI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$212.7M+1.6%	$209.4M+11.9%	$187.1M+31.9%	$141.8M+50.2%	$94.4M+64.6%	$57.4M
Cost of Revenue	$42.9M+4.5%	$41.1M+16.8%	$35.2M+37.8%	$25.5M+51.2%	$16.9M+35.4%	$12.5M
Gross Profit	$169.8M+0.9%	$168.3M+10.7%	$151.9M+30.6%	$116.3M+50.0%	$77.5M+72.7%	$44.9M
R&D Expenses	$20.3M-1.5%	$20.6M+33.3%	$15.4M+13.7%	$13.6M+33.1%	$10.2M+74.5%	$5.8M
SG&A Expenses	$62.7M+12.6%	$55.7M+18.5%	$47.0M+42.5%	$33.0M+79.0%	$18.4M+181.9%	$6.5M
Operating Income	-$54.2M+2.8%	-$55.7M-8.3%	-$51.4M-47.6%	-$34.8M-111.0%	-$16.5M-2031.0%	$855K
Interest Expense	$5.3M+1.2%	$5.3M+1.7%	$5.2M+17.5%	$4.4M+8.3%	$4.1M+46.2%	$2.8M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$59.0M-5.8%	-$55.7M-11.5%	-$50.0M-16.3%	-$43.0M-109.2%	-$20.6M-460.3%	-$3.7M
EPS (Diluted)	$-0.93-3.3%	$-0.90-11.1%	$-0.81-5.2%	$-0.77-79.1%	$-0.43-258.3%	$-0.12

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$47.2M-24.5%	$62.5M+24.5%	$50.2M+6.0%	$47.4M-9.9%	$52.6M-23.5%	$68.7M+52.4%	$45.1M+1.4%	$44.5M
Cost of Revenue	$9.8M-19.2%	$12.1M+15.3%	$10.5M+9.1%	$9.6M-9.8%	$10.7M-19.3%	$13.2M+47.8%	$9.0M+2.0%	$8.8M
Gross Profit	$37.4M-25.8%	$50.4M+26.9%	$39.7M+5.2%	$37.8M-9.9%	$41.9M-24.5%	$55.5M+53.5%	$36.1M+1.3%	$35.7M
R&D Expenses	$4.6M+1.8%	$4.5M-2.9%	$4.7M-14.9%	$5.5M-1.2%	$5.6M+6.8%	$5.2M+5.0%	$5.0M-3.8%	$5.2M
SG&A Expenses	$16.2M+11.4%	$14.5M-10.8%	$16.3M+0.8%	$16.1M+2.2%	$15.8M+16.0%	$13.6M+0.6%	$13.5M-4.9%	$14.2M
Operating Income	-$17.2M-189.9%	-$5.9M+62.2%	-$15.7M+7.6%	-$17.0M-8.9%	-$15.6M-7538.2%	-$204K+98.7%	-$15.1M+29.2%	-$21.4M
Interest Expense	$1.6M+16.3%	$1.4M+0.9%	$1.3M+1.3%	$1.3M+0.8%	$1.3M-0.2%	$1.3M+0.1%	$1.3M+0.1%	$1.3M
Income Tax	N/A	$0	N/A	N/A	N/A	$0	N/A	N/A
Net Income	-$18.0M-91.2%	-$9.4M+42.3%	-$16.3M+6.4%	-$17.4M-9.3%	-$15.9M-3078.0%	-$501K+96.7%	-$15.4M+27.6%	-$21.2M
EPS (Diluted)	$-0.28	N/A	$-0.26+7.1%	$-0.28-12.0%	$-0.25	N/A	$-0.25+26.5%	$-0.34

TMCI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$190.6M-12.2%	$217.1M-13.8%	$251.9M+58.4%	$159.0M+12.9%	$140.8M+236.8%	$41.8M
Current Assets	$132.1M-18.2%	$161.4M-18.6%	$198.4M+48.7%	$133.4M-3.3%	$138.0M+236.7%	$41.0M
Cash & Equivalents	$10.7M-5.7%	$11.3M-12.6%	$13.0M-33.3%	$19.5M-81.6%	$105.8M+485.4%	$18.1M
Inventory	$36.0M-8.2%	$39.3M+34.2%	$29.2M+51.3%	$19.3M+83.0%	$10.6M+35.1%	$7.8M
Accounts Receivable	$42.2M+3.3%	$40.8M+7.1%	$38.1M+30.5%	$29.2M+57.2%	$18.6M+28.2%	$14.5M
Goodwill	$12.8M0.0%	$12.8M0.0%	$12.8M	$0	N/A	N/A
Total Liabilities	$103.2M-0.9%	$104.2M-8.6%	$114.0M+15.7%	$98.5M+106.3%	$47.7M+16.4%	$41.0M
Current Liabilities	$30.6M-12.3%	$34.9M-22.4%	$45.0M+48.9%	$30.2M+66.1%	$18.2M+57.0%	$11.6M
Long-Term Debt	$55.6M+4.3%	$53.3M+0.6%	$53.0M+0.6%	$52.7M+79.5%	$29.4M+0.6%	$29.2M
Total Equity	$87.3M-22.6%	$112.9M-18.2%	$137.9M+127.9%	$60.5M-35.0%	$93.1M+11893.9%	$776K
Retained Earnings	-$249.0M-31.1%	-$190.0M-41.5%	-$134.2M-58.5%	-$84.7M-102.2%	-$41.9M-96.2%	-$21.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$184.1M-3.4%	$190.6M-3.1%	$196.6M-4.8%	$206.4M+0.3%	$205.8M-5.2%	$217.1M+2.0%	$212.9M-5.8%	$226.1M
Current Assets	$123.5M-6.5%	$132.1M-4.3%	$138.0M-6.5%	$147.6M-1.2%	$149.4M-7.4%	$161.4M+2.4%	$157.6M-8.1%	$171.6M
Cash & Equivalents	$9.5M-10.9%	$10.7M+39.3%	$7.7M-4.5%	$8.1M-39.8%	$13.4M+17.8%	$11.3M-6.3%	$12.1M-33.4%	$18.2M
Inventory	$36.4M+0.9%	$36.0M-13.0%	$41.4M-2.3%	$42.4M+11.7%	$37.9M-3.3%	$39.3M-10.0%	$43.6M+5.6%	$41.3M
Accounts Receivable	$30.4M-28.0%	$42.2M+27.9%	$33.0M+8.7%	$30.3M-2.5%	$31.1M-23.8%	$40.8M+68.8%	$24.2M-5.4%	$25.6M
Goodwill	$12.8M0.0%	$12.8M0.0%	$12.8M0.0%	$12.8M0.0%	$12.8M0.0%	$12.8M0.0%	$12.8M0.0%	$12.8M
Total Liabilities	$106.9M+3.5%	$103.2M-3.9%	$107.4M-1.3%	$108.8M+8.3%	$100.5M-3.5%	$104.2M-3.5%	$108.0M-5.2%	$113.9M
Current Liabilities	$34.5M+12.6%	$30.6M-25.1%	$40.9M-2.4%	$41.9M+26.3%	$33.2M-5.0%	$34.9M-8.7%	$38.3M-13.9%	$44.4M
Long-Term Debt	$55.8M+0.4%	$55.6M+3.8%	$53.5M+0.1%	$53.5M+0.1%	$53.4M+0.1%	$53.3M+0.1%	$53.2M+0.1%	$53.2M
Total Equity	$77.2M-11.6%	$87.3M-2.1%	$89.2M-8.6%	$97.6M-7.3%	$105.3M-6.7%	$112.9M+7.6%	$104.9M-6.5%	$112.1M
Retained Earnings	-$267.0M-7.2%	-$249.0M-3.9%	-$239.6M-7.3%	-$223.3M-8.4%	-$205.9M-8.4%	-$190.0M-0.3%	-$189.5M-8.8%	-$174.1M

TMCI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$16.0M+57.0%	-$37.2M-7.5%	-$34.6M-12.8%	-$30.6M-78.3%	-$17.2M-282.6%	-$4.5M
Capital Expenditures	$13.5M+16.6%	$11.6M+1.2%	$11.5M-22.8%	$14.8M+448.5%	$2.7M+153.0%	$1.1M
Free Cash Flow	-$29.5M+39.5%	-$48.8M-5.9%	-$46.0M-1.2%	-$45.5M-128.6%	-$19.9M-257.7%	-$5.6M
Investing Cash Flow	$13.3M-62.5%	$35.4M+143.5%	-$81.3M-6.2%	-$76.5M-2728.8%	-$2.7M-153.0%	-$1.1M
Financing Cash Flow	$2.1M+1198.1%	$160K-99.9%	$109.4M+425.7%	$20.8M-80.7%	$107.7M+835.9%	$11.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$7.2M+190.2%	-$8.0M+11.7%	-$9.1M-198.1%	-$3.0M-172.7%	$4.2M+199.8%	-$4.2M+64.5%	-$11.8M+14.8%	-$13.9M
Capital Expenditures	$3.1M+27.7%	$2.4M-14.6%	$2.8M-41.1%	$4.8M+34.5%	$3.5M+15.3%	$3.1M+7.4%	$2.9M+65.6%	$1.7M
Free Cash Flow	$4.2M+140.1%	-$10.4M+12.4%	-$11.9M-52.2%	-$7.8M-1293.4%	$655K+109.0%	-$7.3M+50.5%	-$14.7M+5.9%	-$15.6M
Investing Cash Flow	-$7.8M-180.9%	$9.7M+10.6%	$8.7M+368.2%	-$3.3M-72.0%	-$1.9M-155.4%	$3.4M-40.6%	$5.8M-74.3%	$22.4M
Financing Cash Flow	-$588K-142.5%	$1.4M+13920.0%	-$10K-101.0%	$987K+450.0%	-$282K-1184.6%	$26K+225.0%	$8K-97.4%	$311K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TMCI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	79.8%-0.6pp	80.4%-0.8pp	81.2%-0.8pp	82.0%-0.1pp	82.1%+3.9pp	78.3%
Operating Margin	-25.5%+1.1pp	-26.6%+0.9pp	-27.5%-2.9pp	-24.6%-7.1pp	-17.5%-19.0pp	1.5%
Net Margin	-27.7%-1.1pp	-26.6%+0.1pp	-26.7%+3.6pp	-30.3%-8.6pp	-21.8%-15.4pp	-6.4%
Return on Equity	-67.6%-18.2pp	-49.4%-13.1pp	-36.3%+34.8pp	-71.0%-49.0pp	-22.1%+450.6pp	-472.7%
Return on Assets	-31.0%-5.3pp	-25.7%-5.8pp	-19.9%+7.2pp	-27.0%-12.4pp	-14.6%-5.8pp	-8.8%
Current Ratio	4.31-0.3	4.62+0.2	4.400.0	4.41-3.2	7.58+4.0	3.53
Debt-to-Equity	0.64+0.2	0.47+0.1	0.38-0.5	0.87+0.6	0.32-37.3	37.61
FCF Margin	-13.9%+9.4pp	-23.3%+1.3pp	-24.6%+7.5pp	-32.1%-11.0pp	-21.1%-11.4pp	-9.7%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	79.3%-1.4pp	80.6%+1.6pp	79.1%-0.6pp	79.7%-0.0pp	79.7%-1.0pp	80.7%+0.6pp	80.1%-0.1pp	80.3%
Operating Margin	-36.4%-26.9pp	-9.5%+21.7pp	-31.2%+4.6pp	-35.8%-6.2pp	-29.6%-29.3pp	-0.3%+33.3pp	-33.6%+14.5pp	-48.1%
Net Margin	-38.0%-23.0pp	-15.0%+17.4pp	-32.4%+4.3pp	-36.7%-6.4pp	-30.3%-29.6pp	-0.7%+33.3pp	-34.1%+13.6pp	-47.7%
Return on Equity	-23.3%-12.5pp	-10.8%+7.5pp	-18.3%-0.4pp	-17.8%-2.7pp	-15.1%-14.7pp	-0.4%+14.2pp	-14.6%+4.3pp	-18.9%
Return on Assets	-9.8%-4.8pp	-4.9%+3.4pp	-8.3%+0.1pp	-8.4%-0.7pp	-7.7%-7.5pp	-0.2%+7.0pp	-7.2%+2.2pp	-9.4%
Current Ratio	3.58-0.7	4.31+0.9	3.37-0.1	3.52-1.0	4.50-0.1	4.62+0.5	4.12+0.3	3.86
Debt-to-Equity	0.72+0.1	0.64+0.0	0.60+0.1	0.55+0.0	0.51+0.0	0.47-0.0	0.51+0.0	0.47
FCF Margin	8.8%+25.5pp	-16.7%+7.0pp	-23.7%-7.2pp	-16.5%-17.8pp	1.3%+11.8pp	-10.6%+22.0pp	-32.6%+2.5pp	-35.1%

Similar Companies

Orthopedia KIDS

$493.5M

Bioventus Inc. BVS

$817.0M

Cytek Biosciences, Inc. CTKB

$596.6M

Surmodics Inc SRDX

$614.5M

CeriBell, Inc. CBLL

$710.3M

Frequently Asked Questions

What is Treace Medical Concepts, Inc.'s annual revenue?

Treace Medical Concepts, Inc. (TMCI) reported $212.7M in total revenue for fiscal year 2025. This represents a 1.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Treace Medical Concepts, Inc.'s revenue growing?

Treace Medical Concepts, Inc. (TMCI) revenue grew by 1.6% year-over-year, from $209.4M to $212.7M in fiscal year 2025.

Is Treace Medical Concepts, Inc. profitable?

No, Treace Medical Concepts, Inc. (TMCI) reported a net income of -$59.0M in fiscal year 2025, with a net profit margin of -27.7%.

What is Treace Medical Concepts, Inc.'s EBITDA?

Treace Medical Concepts, Inc. (TMCI) had EBITDA of -$43.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Treace Medical Concepts, Inc. have?

As of fiscal year 2025, Treace Medical Concepts, Inc. (TMCI) had $10.7M in cash and equivalents against $55.6M in long-term debt.

What is Treace Medical Concepts, Inc.'s gross margin?

Treace Medical Concepts, Inc. (TMCI) had a gross margin of 79.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Treace Medical Concepts, Inc.'s operating margin?

Treace Medical Concepts, Inc. (TMCI) had an operating margin of -25.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Treace Medical Concepts, Inc.'s net profit margin?

Treace Medical Concepts, Inc. (TMCI) had a net profit margin of -27.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Treace Medical Concepts, Inc.'s return on equity (ROE)?

Treace Medical Concepts, Inc. (TMCI) has a return on equity of -67.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Treace Medical Concepts, Inc.'s free cash flow?

Treace Medical Concepts, Inc. (TMCI) generated -$29.5M in free cash flow during fiscal year 2025. This represents a 39.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Treace Medical Concepts, Inc.'s operating cash flow?

Treace Medical Concepts, Inc. (TMCI) generated -$16.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Treace Medical Concepts, Inc.'s total assets?

Treace Medical Concepts, Inc. (TMCI) had $190.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Treace Medical Concepts, Inc.'s capital expenditures?

Treace Medical Concepts, Inc. (TMCI) invested $13.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Treace Medical Concepts, Inc. spend on research and development?

Treace Medical Concepts, Inc. (TMCI) invested $20.3M in research and development during fiscal year 2025.

What is Treace Medical Concepts, Inc.'s current ratio?

Treace Medical Concepts, Inc. (TMCI) had a current ratio of 4.31 as of fiscal year 2025, which is generally considered healthy.

What is Treace Medical Concepts, Inc.'s debt-to-equity ratio?

Treace Medical Concepts, Inc. (TMCI) had a debt-to-equity ratio of 0.64 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Treace Medical Concepts, Inc.'s return on assets (ROA)?

Treace Medical Concepts, Inc. (TMCI) had a return on assets of -31.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Treace Medical Concepts, Inc.'s cash runway?

Based on fiscal year 2025 data, Treace Medical Concepts, Inc. (TMCI) had $10.7M in cash against an annual operating cash burn of $16.0M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Treace Medical Concepts, Inc.'s Altman Z-Score?

Treace Medical Concepts, Inc. (TMCI) has an Altman Z-Score of 0.61, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Treace Medical Concepts, Inc.'s Piotroski F-Score?

Treace Medical Concepts, Inc. (TMCI) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Treace Medical Concepts, Inc.'s earnings high quality?

Treace Medical Concepts, Inc. (TMCI) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Treace Medical Concepts, Inc. cover its interest payments?

Treace Medical Concepts, Inc. (TMCI) has an interest coverage ratio of -10.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Treace Medical Concepts, Inc.?

Treace Medical Concepts, Inc. (TMCI) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.